MYRIAD GENETICS INC (MYGN)

5.22 0.21 (4.29%)

As of 2026-03-03 13:36:17 EST

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.

Traded asNasdaq: MYGN
ISINUS62855J1043
CIK0000899923
LEI52990044IHUOUMETT163
EIN870494517
SectorHealthcare
IndustryIn Vitro & In Vivo Diagnostic Substances
CEOSam Raha
Employees2,600
Fiscal Year End1231
Address322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
Phone801-584-3600
Websitehttps://myriad.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
MYGNMYRIAD GENETICS INC2026-03-03 13:36:175.220.214.29
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
MYGN0000899923MYRIAD GENETICS INCUS62855J104352990044IHUOUMETT163870494517Nasdaq2835In Vitro & In Vivo Diagnostic Substances1231DE322 NORTH 2200 WESTSALT LAKE CITYUT84116UNITED STATESUS801-584-3600322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116MYRIAD GENETICS INCHealthcare1991Sam Raha2,600https://myriad.com494,049,87693,500,00093,508,165Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.2026-02-26 18:51:09
This is a preview of the latest data. Subscribe to access the full data.
MYGN Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
MYGN Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2025494,049,876-1,727,330,838-77.759393,508,1652,199,1012.4084
20242,221,380,714323,400,73817.039291,309,0641,434,1781.5957
20231,897,979,976432,884,48929.546589,874,8868,651,17310.651
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Samraat S. RahaChief Operating Officer2024750,00002,910,681706,50022,1464,389,327
Mark S. VerrattiChief Commercial Officer2024552,34402,646,082489,72024,0723,712,217
Paul J. DiazChief Executive Officer, President20241,120,875011,113,5141,356,75039,46113,630,599
R. Bryan RiggsbeeChief Financial Officer202470,55500049,296119,851
Dale MuzzeyChief Scientific Officer2024499,35002,222,701265,10018,7273,005,878
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20252,700
20242,700
20232,700
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue824,500,000837,600,000753,200,000
Cost Of Revenue247,900,000252,200,000236,200,000
Gross Profit576,600,000585,400,000—
Research And Development Expenses106,800,000113,400,00088,700,000
General And Administrative Expenses256,800,000275,900,000572,900,000
Operating Expenses963,800,000708,900,0001,010,600,000
Operating Income-387,200,000-123,500,000-257,400,000
Net Income-365,900,000-127,300,000-263,300,000
Earnings Per Share Basic-3.95-1.41-3.18
Earnings Per Share Diluted-3.95-1.41-3.18
Weighted Average Shares Outstanding Basic92,600,00090,600,00082,800,000
Weighted Average Shares Outstanding Diluted92,600,00090,600,00082,800,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents149,600,000102,400,000132,100,000
Marketable Securities Current—08,800,000
Accounts Receivable115,300,000121,200,000114,300,000
Inventories30,600,00027,500,00022,000,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current332,600,000298,000,000313,600,000
Marketable Securities Non Current——0
Property Plant And Equipment114,000,000117,400,000119,000,000
Other Assets Non Current5,600,0008,500,00015,400,000
Total Assets Non Current374,000,000729,500,000832,900,000
Total Assets706,600,0001,027,600,0001,146,500,000
Accounts Payable30,000,00032,300,00025,800,000
Deferred Revenue——500,000
Short Term Debt———
Other Liabilities Current96,900,000119,000,000113,900,000
Total Liabilities Current133,800,000164,100,000155,900,000
Long Term Debt119,900,00039,600,00038,500,000
Other Liabilities Non Current1,700,0002,200,00041,300,000
Total Liabilities Non Current204,800,000162,400,000207,400,000
Total Liabilities338,600,000326,500,000363,300,000
Common Stock900,000900,000900,000
Retained Earnings-1,122,700,000-756,800,000-629,500,000
Accumulated Other Comprehensive Income800,000-800,000-3,700,000
Total Shareholders Equity368,000,000701,100,000783,200,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization53,700,00061,200,00061,900,000
Share Based Compensation Expense35,200,00049,800,00040,700,000
Other Non Cash Income Expense———
Change In Accounts Receivable-6,200,0008,700,00012,500,000
Change In Inventories3,200,0006,200,0001,800,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-1,400,0004,700,000-3,700,000
Change In Other Liabilities-27,500,000-41,000,00027,400,000
Cash From Operating Activities1,800,000-8,700,000-110,900,000
Purchases Of Marketable Securities—00
Sales Of Marketable Securities09,000,00090,400,000
Acquisition Of Property Plant And Equipment———
Acquisition Of Business—00
Other Investing Activities———
Cash From Investing Activities-27,400,000-11,900,00031,900,000
Tax Withholding For Share Based Compensation7,300,00013,400,0008,800,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt80,500,000119,500,00040,000,000
Other Financing Activities-200,0005,900,0006,000,000
Cash From Financing Activities64,200,000-7,400,000152,900,000
Change In Cash39,400,000-29,000,00074,500,000
Cash At End Of Period149,600,000102,400,000132,100,000
Income Taxes Paid—2,700,0001,900,000
Interest Paid8,400,0001,900,0001,400,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-3.95-1.41-3.18
Price To Earnings Ratio-1.557-9.7234-6.0189
Earnings Growth Rate180.1418-55.6604128.777
Price Earnings To Growth Ratio-0.00860.1747-0.0467
Book Value Per Share3.97417.73849.4589
Price To Book Ratio1.54751.77172.0235
Ebitda-301,700,000-60,600,000-196,600,000
Enterprise Value539,790,0001,179,326,0001,491,192,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.32580.05650.0492
Capital Expenditures50,300,00059,600,00097,500,000
Free Cash Flow-48,500,000-68,300,000-208,400,000
Return On Equity-0.9943-0.1816-0.3362
One Year Beta1.18971.11311.35
Three Year Beta1.20981.36611.4404
Five Year Beta1.33761.34531.3801
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Solaiman ShereenChief People Officer2026-03-011,675D109,288
Phanstiel S. LouiseDirector2026-02-2748,000A281,951
Phanstiel S. LouiseDirector2026-02-2650,407A233,951
Phanstiel S. LouiseDirector2026-02-256,100A183,544
Haas Kevin RichardChief Technology Officer2026-02-0223,697A202,332
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Caitong International Asset Management Co., Ltd2025-12-31203336.1515
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO2025-12-3168,00010,9976.1835
MAI Capital Management2025-12-31302496.1633
Arax Advisory Partners2025-12-316,7721,1016.1508
VIRTUS ADVISERS, LLC2025-12-31123,00020,0006.15
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
RYDEX SERIES FUNDS2025-12-31Class CRYCMX128787.20.0093
RYDEX SERIES FUNDS2025-12-31Class ARYAKX128787.20.0093
RYDEX SERIES FUNDS2025-12-31Class HRYMKX128787.20.0093
RYDEX DYNAMIC FUNDS2025-12-31H-Class SharesRYRSX4642,853.60.0052
RYDEX DYNAMIC FUNDS2025-12-31C-Class SharesRYRLX4642,853.60.0052
This is a preview of the latest data. Subscribe to access the full data.